Guangxi Wuzhou Zhongheng Group Co Ltd (600252) fair value: what the stock is really worth
As of Oct 8, 2026: fair value of Guangxi Wuzhou Zhongheng Group Co Ltd ¥0.26, price ¥2.17, upside -88.0%, quality 48 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 1, 2026.
How to read this chart
60‑month range ¥1.76 – ¥4.04 · fair‑value band ¥0.1400 – ¥0.3700 · the ¥2.17 price screens above the ¥0.2600 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Oct 1, 2026.
Follow Guangxi Wuzhou Zhongheng Group Co in your weekly email
Every Wednesday you see whether Guangxi Wuzhou Zhongheng Group Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Guangxi Wuzhou Zhongheng Group Co., Ltd, together with its subsidiaries, researches, develops, manufactures, and sells pharmaceuticals in China.
Show more
Guangxi Wuzhou Zhongheng Group Co., Ltd, together with its subsidiaries, researches, develops, manufactures, and sells pharmaceuticals in China. The company offers traditional Chinese medicine, including Xueshuantong injection, Zhonghua Dieda Wan for traumatic injuries, Fuyanjing capsules, JieShiTong tablets, snake gall and fritillaria liquid, Kunyuean granules, and compound clam oral liquid for cardiovascular and cerebrovascular, neurology, endocrinology, orthopedics, ophthalmology, gynecology, pediatrics, respiratory, urinary system, and other healthcare applications. It also provides clindamycin hydrochloride injection, esomeprazole sodium injection, esomeprazole magnesium enteric-coated capsules, cefoperazone dry suspension, naloxone hydrochloride injection, and fludarabine phosphate injection. Further, the company is involved in production of oral care, clothing care, and home care products, including toothpaste; health food business; pharmaceutical distribution; project investment and management; real estate development and operation; and cosmetic products businesses. Guangxi Wuzhou Zhongheng Group Co., Ltd was founded in 1993 and is based in Wuzhou, China.
Stock analysis
Guangxi Wuzhou Zhongheng Group Co Ltd (600252) currently trades at ¥2.17, while our model-based Fair Value estimate is ¥0.2600, 88.0% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of ¥1.13 per share, and 0 of the 3 models we run sit above the ¥2.17 price.
Bear case: the Dividend Discount group reads lowest at ¥0.2000, and 3 of the 3 models stay below the price. Evidence for this calculation is low.
Scenario range: ¥0.1400 (bear) to ¥0.3700 (bull), the price of ¥2.17 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Guangxi Wuzhou Zhongheng Group Co Ltd reported revenue of 1.7B CNY in FY2025 versus 3.2B CNY in FY2021, a compound −13.8%/yr. Reported net income was −357M CNY in FY2025.
Key figures
Market cap 6.9B CNY (≈ $1.0B) · P/S ratio 4.86 · EPS (TTM) ¥−0.1400 · Dividend yield 0.8% · Net margin −20.4% · Return on equity −8.3% · Return on assets (EBIT) −0.7% · Operating margin 0.4%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (medium confidence).
What moves the price
The share trades about 28% below its 52-week high and 23% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −22% fair-value upside, at −88%, 600252 screens richer than that median.
Fair Value models
Bear ¥0.1400Fair Value ¥0.2600Bull ¥0.3700
Price ¥2.17 · Upside -88.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−23.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−13.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−13.8%
Start year 2020 (pandemic). Over 10 years: +2.7% a year
Revenue growth 28 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.6%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
9.4% (2020) → −10.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Guangxi Wuzhou Zhongheng Group Co Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 585 stocks
Beats the industry median on 2/10 measures
Overall it trails its industry peers.
Valuation
Quality Score48 · Below median
Fair Value upside−88.0% · Bottom 25%
Profitability
Return on assets−1.6% · Bottom 25%
Net margin (TTM)−29.9% · Bottom 25%
Operating margin (TTM)0.4% · Below median
Growth and dividend
Revenue growth−27.4% · Bottom 25%
Dividend yield (TTM)0.8% · Below median
Balance sheet
Debt / equity0.09× · Above median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/B0.19× · Cheapest 25%
P/S (TTM)0.72× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 19
FUTURE (revenue growth)0· sector 24
PAST (return on equity)0· sector 27
HEALTH (low debt)96· sector 96
DIVIDEND (yield)16· sector 31
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Guangxi Wuzhou Zhongheng Group Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/600252
Frequently asked questions
Is Guangxi Wuzhou Zhongheng Group Co Ltd (600252) overvalued or undervalued?
As of Oct 1, 2026, our model estimates a fair value of ¥0.2600 versus a price of ¥2.17, about −88% upside (overvalued).
What is the fair value of 600252?
Our model-based fair value for Guangxi Wuzhou Zhongheng Group Co Ltd is ¥0.2600 (as of Oct 1, 2026), built from audited fundamentals. The current price: ¥2.17.
What is the quality score of 600252?
Guangxi Wuzhou Zhongheng Group Co Ltd has a Quality Score of 48/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Guangxi Wuzhou Zhongheng Group Co Ltd (600252)?
Our model-based price target is the fair value of ¥0.2600 (as of Oct 1, 2026) from 3 valuation models. Cautious scenario ¥0.1400, optimistic scenario ¥0.3700. It is a calculation from audited fundamentals, not an analyst target.
What is the Guangxi Wuzhou Zhongheng Group Co Ltd stock forecast for 2026?
Our models put fair value at ¥0.2600, about −88% upside versus a price of ¥2.17 (overvalued). Cautious scenario ¥0.1400, optimistic scenario ¥0.3700. The calculation is refreshed regularly with new filings.
What is the revenue of Guangxi Wuzhou Zhongheng Group Co Ltd (600252)?
Guangxi Wuzhou Zhongheng Group Co Ltd reported trailing-twelve-month revenue of about 1.4B CNY (latest available figure, as of Oct 1, 2026).
Does Guangxi Wuzhou Zhongheng Group Co Ltd pay a dividend?
Guangxi Wuzhou Zhongheng Group Co Ltd currently shows a dividend yield of about 0.79% relative to its recent price (as of Oct 1, 2026).
What is the intrinsic value of Guangxi Wuzhou Zhongheng Group Co Ltd (600252)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Guangxi Wuzhou Zhongheng Group Co Ltd it is ¥0.2600 per share (as of Oct 1, 2026), against a price of ¥2.17. It is the blended result of 3 valuation models (cash flow, earnings, asset, dividend).
Is Guangxi Wuzhou Zhongheng Group Co Ltd stock overvalued or undervalued in 2026?
As of Oct 1, 2026, 600252 trades above its calculated fair value: price ¥2.17, fair value ¥0.2600, a gap of about −88% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 600252?
No. The price is what the market pays today (¥2.17); the fair value is what the company's own numbers justify (¥0.2600). For Guangxi Wuzhou Zhongheng Group Co Ltd the two are ¥1.91 per share apart. That gap is exactly why we show both numbers side by side.
How much is Guangxi Wuzhou Zhongheng Group Co Ltd worth?
The market values Guangxi Wuzhou Zhongheng Group Co Ltd at about 6.9B CNY (market capitalisation, as of Oct 1, 2026). Per share that is ¥2.17; our models calculate a fair value of ¥0.2600 per share.
What do the bullish and bearish scenarios say about 600252?
Our models span a range for Guangxi Wuzhou Zhongheng Group Co Ltd: cautious scenario ¥0.1400, base ¥0.2600, optimistic ¥0.3700 per share (as of Oct 1, 2026, price ¥2.17). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Guangxi Wuzhou Zhongheng Group Co Ltd (600252)?
Balance-sheet figures for Guangxi Wuzhou Zhongheng Group Co Ltd (as of Oct 1, 2026): return on equity −8.3%, debt of 0.09 per unit of equity. They feed the Quality Score of 48/100, which measures business quality independently of the share price.
How far is 600252 from its 52-week high?
Guangxi Wuzhou Zhongheng Group Co Ltd trades at ¥2.17, about 28% below its 52-week high of ¥3.01 and 23% above the low of ¥1.76 (as of Oct 8, 2026). Distance from the high says nothing about value: that is what the fair value of ¥0.2600 is for.
Which stocks are comparable to Guangxi Wuzhou Zhongheng Group Co Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Guangxi Wuzhou Zhongheng Group Co Ltd stock attractive at the current price?
The data as of Oct 1, 2026: price ¥2.17, calculated fair value ¥0.2600 (−88%), Quality Score 48/100, from 3 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 600252 calculated?
We run Guangxi Wuzhou Zhongheng Group Co Ltd through 3 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥0.2600, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Guangxi Wuzhou Zhongheng Group Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Guangxi Wuzhou Zhongheng Group Co Ltd (600252)?
The closing price on Oct 8, 2026 was ¥2.17. Our model-based fair value is ¥0.2600, about −88% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Guangxi Wuzhou Zhongheng Group Co Ltd right now?
The price sits above even our optimistic bull case (¥0.3700). The favourable scenario is already priced in. The model range is unusually wide (¥0.1400 to ¥0.3700). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (48/100) and above fair value, neither a clear bargain nor a standout compounder.
Where does the earnings growth of Guangxi Wuzhou Zhongheng Group Co Ltd (600252) come from?
Earnings per share at Guangxi Wuzhou Zhongheng Group Co Ltd grew −25.2 % a year from 2013 to 2024. Broken into its drivers: revenue per share +0.1 %, EBIT margin −25.8 %, tax rate −3.3 %, residual (interest, one-offs) +4.2 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Guangxi Wuzhou Zhongheng Group Co Ltd
How large is the market capitalisation of Guangxi Wuzhou Zhongheng Group Co Ltd (600252)?
The market capitalisation of Guangxi Wuzhou Zhongheng Group Co Ltd is 6.9B CNY (≈ $1.0B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Guangxi Wuzhou Zhongheng Group Co Ltd (600252)?
The price-to-sales ratio of Guangxi Wuzhou Zhongheng Group Co Ltd is 4.86 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Guangxi Wuzhou Zhongheng Group Co Ltd (600252)?
Earnings per share at Guangxi Wuzhou Zhongheng Group Co Ltd are ¥−0.1400. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Guangxi Wuzhou Zhongheng Group Co Ltd (600252)?
The dividend yield of Guangxi Wuzhou Zhongheng Group Co Ltd is 0.8%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Guangxi Wuzhou Zhongheng Group Co Ltd (600252)?
The net margin of Guangxi Wuzhou Zhongheng Group Co Ltd is −20.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Guangxi Wuzhou Zhongheng Group Co Ltd (600252)?
The return on equity (ROE) of Guangxi Wuzhou Zhongheng Group Co Ltd is −8.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Guangxi Wuzhou Zhongheng Group Co Ltd (600252)?
On an EBIT basis the return on assets of Guangxi Wuzhou Zhongheng Group Co Ltd is −0.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Guangxi Wuzhou Zhongheng Group Co Ltd (600252)?
The operating margin of Guangxi Wuzhou Zhongheng Group Co Ltd is 0.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Guangxi Wuzhou Zhongheng Group Co Ltd (600252)?
Revenue at Guangxi Wuzhou Zhongheng Group Co Ltd is growing −27.4% versus a year earlier (3y avg −13.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Guangxi Wuzhou Zhongheng Group Co Ltd (600252)?
Earnings per share at Guangxi Wuzhou Zhongheng Group Co Ltd are growing −65.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Guangxi Wuzhou Zhongheng Group Co Ltd (600252) generate?
The free cash flow of Guangxi Wuzhou Zhongheng Group Co Ltd is −120M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Guangxi Wuzhou Zhongheng Group Co Ltd (600252) hold?
Guangxi Wuzhou Zhongheng Group Co Ltd holds more cash than debt, 2.3B CNY net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Guangxi Wuzhou Zhongheng Group Co Ltd in the live analysis
One click puts Guangxi Wuzhou Zhongheng Group Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.
